Prophylactic human papillomavirus (HPV) vaccine represents a revolutionary step forward in
preventing HPV-related cancers, especially cervical carcinoma. Alongside appropriate …

Cervical cancer incidence and mortality have decreased in high-income countries, but low-
and middle-income countries continue to bear a significant burden from the disease. Human …

Clin Microbiol Infect 2012; 18 (Suppl. 5): 64–69 Abstract Two prophylactic human
papillomavirus (HPV) vaccines have been recently approved: one quadrivalent and the …

Human papillomavirus (HPV) is causatively associated with cervical cancer (CC), the fourth
most common malignant disease of women worldwide. The introduction of first generation …

Introduction Human papillomavirus (HPV) infection, which poses significant disease burden,
is decreasing following implementation of vaccination programs. Synthesized evidence on …

The human papillomavirus (HPV) represents one of the most common sexually transmitted
infections and it has been related to cervical cancer. The HPV vaccines prevent infection …

Objectives Despite their use, differences in human papillomavirus (HPV) vaccine efficacies
remain uncertain. This study assesses efficacy differences among bivalent, quadrivalent …

Cervical cancer is one of the most common cancers in women aged 15-44 years in the
world, with more than three-quarters of cases diagnosed at a locally advanced clinical stage …

Human papillomavirus (HPV) is the most common sexually transmitted disease, worldwide.
Primary prevention thorough vaccination si able to reduce the burden of HPV-related …

Background: Human papillomavirus (HPV) is now known to be a necessary cause of
cervical cancer, and prophylactic HPV vaccines aimed at preventing genital warts …